- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07942805
Dexamethasone Doses and Glycemic Response in Diabetic Cholecystectomy
Effect of Two Different Doses of Intraoperative Dexamethasone on Glycemic Response in Diabetic Patients Undergoing Laparoscopic Cholecystectomy
This randomized double-blind controlled trial aims to compare the effects of two different doses of intraoperative intravenous dexamethasone (4 mg versus 8 mg) versus placebo on perioperative glycemic response in adult patients with diabetes mellitus undergoing laparoscopic cholecystectomy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Diabetes mellitus is a common comorbidity in patients undergoing surgery. Perioperative hyperglycemia is associated with increased morbidity. Dexamethasone is frequently administered intraoperatively for its antiemetic and anti-inflammatory effects, but it can cause hyperglycemia.
This randomized double-blind trial will allocate adult patients with established diabetes mellitus scheduled for elective laparoscopic cholecystectomy into three groups: Group I (4 mg dexamethasone), Group II (8 mg dexamethasone), and Group III (placebo). Blood glucose will be measured at predefined time points using a glucometer. The primary outcome is the maximum recorded perioperative blood glucose concentration within 24 hours after dexamethasone administration.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Arwa M Mostafa, Resident
- Telefonnummer: 01012885077
- E-post: Arwa.18313470@med.aun.edu.eg
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- - Adult patients aged 18 to 60 years.
- Established diabetes mellitus.
- Scheduled for elective laparoscopic cholecystectomy under general anesthesia.
- Written informed consent.
Exclusion Criteria:
- - Patient refusal.
- Morbid obesity, cardiac diseases, hepatic diseases, or renal diseases.
- Endocrine disorders affecting glucose metabolism other than diabetes mellitus.
- Type 1 diabetes mellitus requiring continuous insulin infusion.
- Poorly controlled diabetes mellitus (HbA1c > 9.0%).
- ASA physical status III-IV.
- Recent parenteral or oral steroid therapy.
- Allergy to dexamethasone.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: 4 mg Dexamethasone
Patients will receive 4 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds. |
Intravenous 4 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.
Andre navn:
|
|
Eksperimentell: 8 mg Dexamethasone
Patients will receive 8 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds. |
Intravenous 8 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.
Andre navn:
|
|
Placebo komparator: Placebo
Patients will receive an equivalent volume of 0.9% normal saline intravenously as placebo. |
Equivalent volume of 0.9% normal saline intravenously.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Perioperative Blood Glucose Concentration
Tidsramme: At 24 hours
|
Maximum recorded perioperative blood glucose concentration in mg/dL within 24 hours after dexamethasone administration, measured by finger-prick capillary blood glucose using a glucometer. |
At 24 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Peak Blood Glucose Concentration
Tidsramme: At 24 hours
|
Mean time in hours from dexamethasone administration to peak blood glucose concentration. |
At 24 hours
|
|
Proportion of Patients Developing Hyperglycemia
Tidsramme: At 24 hours
|
Proportion of patients developing blood glucose > 180 mg/dL. |
At 24 hours
|
|
Proportion of Patients Developing Severe Hyperglycemia
Tidsramme: At 24 hours
|
Proportion of patients developing blood glucose > 200 mg/dL or > 250 mg/dL. |
At 24 hours
|
|
Requirement for Rescue Insulin
Tidsramme: At 24 hours
|
Proportion of patients requiring rescue insulin during the first 24 postoperative hours. |
At 24 hours
|
|
Incidence of Hypoglycemia
Tidsramme: At 24 hours
|
Proportion of patients developing blood glucose < 70 mg/dL. |
At 24 hours
|
|
Postoperative Nausea and Vomiting
Tidsramme: At 24 hours
|
Incidence of postoperative nausea and vomiting. |
At 24 hours
|
|
Surgical Site Infection
Tidsramme: At 30 days
|
Incidence of surgical site infection. |
At 30 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Ola M Wahba, prof, Anaesthesia , ICU and pain management Department, Assiut University Hospitals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Metabolske sykdommer
- Glukosemetabolismeforstyrrelser
- Ernæringsmessige og metabolske sykdommer
- Sukkersyke
- Hyperglykemi
- Farmasøytiske preparater
- Polysykliske forbindelser
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Steroider, fluorert
- Krystalloidløsninger
- Isotoniske løsninger
- Løsninger
- Gravadienetrioler
- Deksametason
- Saltoppløsning
Andre studie-ID-numre
- Dexa-Diabetic-Chole-2026
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .